Mariner
AMLX icon

Mariner’s Amylyx Pharmaceuticals AMLX Stock Holding History

Mariner’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,342
Closed -$560K – 3555
2025
Q4 		$560K Sell
46,342
-1,685
-4% -$22.9K ﹤0.01% 2367
2025
Q3 		$653K Sell
48,027
-641
-1% -$6.03K ﹤0.01% 2218
2025
Q2 		$312K Sell
48,668
-2,238
-4% -$10.9K ﹤0.01% 2699
2025
Q1 		$180K Buy
50,906
+367
+0.7% +$1.31K ﹤0.01% 3041
2024
Q4 		$191K Sell
50,539
-5,795
-10% -$27.3K ﹤0.01% 3018
2024
Q3 		$183K Sell
56,334
-1,205
-2% -$2.71K ﹤0.01% 2961
2024
Q2 		$109K Buy
57,539
+8,271
+17% +$16K ﹤0.01% 2940
2024
Q1 		$140K Sell
49,268
-163
-0.3% -$2.13K ﹤0.01% 2861
2023
Q4 		$728K Buy
49,431
+806
+2% +$12.4K ﹤0.01% 1665
2023
Q3 		$890K Sell
48,625
-17
-0% -$359 ﹤0.01% 1384
2023
Q2 		$1.05M Buy
48,642
+37
+0.1% +$999 ﹤0.01% 1279
2023
Q1 		$1.43M Buy
48,605
+10,614
+28% +$369K ﹤0.01% 1109
2022
Q4 		$1.4M Buy
+37,991
New +$1.35M ﹤0.01% 1082

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Mariner's AMLX Position: Q1 2026 in Review

Mariner sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 46,342 shares — an estimated $560K sold.

Mariner first reported a position in AMLX in Q4 2022 and held it in 13 quarters. The position peaked at $1.43M in Q1 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Mariner reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mariner sold 46,342 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $560K.
  • Mariner first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 13 quarters.
  • Mariner's Amylyx Pharmaceuticals position peaked at $1.43M in Q1 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.